Sjogren’s Treatment Report

www.SjogrensTreatmentReport.com

News

Ask the Expert: CBD Oil and Sjögren’s

https://www.sjogrens.org/blog/2020/ask-the-expert-cbd-oil-and-sjogrens

Ask the Expert: CBD Oil and Sjögren’s
Ask the Expert, Symptoms, Treatment — Aug 12, 2020

Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome

https://www.einnews.com/pr_news/521168729/luminary-therapeutics-and-case-western-reserve-university-enter-formal-collaboration-for-development-of-baff-car

Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome

Luminary Tx and CWRU enter formal collaboration for clinical development of novel BAFF CAR to treat Mantle Cell Lymphoma and Sjogren’s Syndrome

MINNEAPOLIS, MN, USA, July 7, 2020 /EINPresswire.com/ — Luminary Therapeutics (Luminary Tx) and Case Western Reserve University have entered into a formal collaboration agreement that includes an option for Luminary to exclusively license a novel BAFF target for use in CAR-T (chimeric antigen receptor T cells) constructs.

The BAFF target was discovered by Reshmi Parameswaran, PhD, an assistant professor at the Case Western Reserve School of Medicine and a faculty member in the Division of Hematology and Oncology, Department of Medicine, and the Seidman Cancer Center at University Hospitals (UH) in Cleveland.

Luminary intends to conduct IND-enabling non-clinical studies to support two clinical trials with its novel and proprietary non-viral autologous BAFF CAR-T (LMY-920) to treat Mantle Cell Lymphoma and Sjogren’s Syndrome. This BAFF target is unique in that it binds to three distinct receptors (BAFF, BCMA, and TACI). Additionally, this BAFF target avoids early B-Cells while targeting more mature B-Cells that express one of three antigens.

Study identifies CP-25 as a potential drug for the treatment of primary Sjögren’s syndrome

New research published in Nature’s Laboratory Investigation shows that CP-25 “increased saliva flow, alleviated the salivary gland indexes, and improved tissue integrity” in a mouse model of primary Sjogren’s syndrome.

Researchers “identified the underlying mechanisms of the therapeutic effect of CP-25 and provided an experimental foundation for CP-25 as a potential drug in the treatment of the human autoimmune disorder pSS [primary Sjögren’s syndrome].”

The study titled, CP-25 alleviates antigen-induced experimental Sjögren’s syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration, was published on July 3, 2020 and funded by the National Nature Science Foundation of China, the Provincial Natural Science Research Project of Anhui Province, and the Key Projects of Anhui Province University Outstanding Youth Talent Fund.

Newsletter

Subscribe to email updates about CP-25 and other promising new treatments for Sjogren’s syndrome. (Free. One email per week. No spam.)

References

https://www.nature.com/articles/s41374-020-0453-0

https://pubmed.ncbi.nlm.nih.gov/32620868/

https://doi.org/10.1038/S41374-020-0453-0

Contact

Comments, questions, feedback? Send an email to michael@urgentresearch.com and say hello.

Wize Pharma Completes Patient Enrollment In Phase 4 Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome

https://www.prnewswire.com/news-releases/wize-pharma-completes-patient-enrollment-in-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome-300990264.html

Wize Pharma Completes Patient Enrollment In Phase IV Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome

– Topline Results Expected Q2 2020
– Study designed to support approval pathway in the U.S. and other major markets

Jan 21, 2020, 09:00 ET

HOD HASHARON, Israel, Jan. 21, 2020 /PRNewswire/ — Wize Pharma, Inc. (OTCQB: WIZP) (“Wize”), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has completed enrolment in its Phase IV clinical trial of its eye drop formula to evaluate the efficacy of LO2A for the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome.

The Challenge of Identifying Sjogren’s Syndrome

The Challenge of Identifying Sjogren’s Syndrome

The main symptoms — dry eyes and mouth, fatigue and limb pain — are common complaints associated with any number of health problems.

Back to top